

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT5325772

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
SUZHOU PENGXU PHARMATECH CO. LTD.	06/12/2017
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	ESTEVE QUIMICA S.A.
<b>Street Address:</b>	BARCELONA AVDA.
<b>Internal Address:</b>	MARE DE DEU DE MONTSERRAT 12
<b>City:</b>	BARCELONA
<b>State/Country:</b>	SPAIN
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	15575373
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(203)487-9815
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	2038064700
<b>Email:</b>	kcheng@vlpawgroup.com
<b>Correspondent Name:</b>	VLP LAW GROUP LLP
<b>Address Line 1:</b>	12 JACKSON STREET
<b>Address Line 4:</b>	COS COB, CONNECTICUT 06807
<b>ATTORNEY DOCKET NUMBER:</b>	3519-01US
<b>NAME OF SUBMITTER:</b>	KENT H. CHENG
<b>SIGNATURE:</b>	/Kent H. Cheng/
<b>DATE SIGNED:</b>	01/15/2019
<b>Total Attachments: 2</b>	
source=Assignment Pengxu to Esteve 3519-01US#page1.tif	
source=Assignment Pengxu to Esteve 3519-01US#page2.tif	

## ASSIGNMENT

In consideration of One Dollar (\$1.00), and other good and valuable consideration in the framework of the Co-Development and Collaboration Agreement entered into in Barcelona, on October 31st, 2016, by and between Esteve Quimica S.A. and Suzhou PengXu Pharmatech Co. Ltd., the receipt of which is hereby acknowledged, the undersigned, **Suzhou PengXu Pharmatech Co. Ltd.**, a Chinese company with domicile in 3rd Floor, Building 7, 2358 ChangAn Road, Wujiang Suzhou JiangSu 215200, China (hereinafter referred to as "ASSIGNOR"):

Hereby sell, assign and transfer to **ESTEVE QUIMICA S.A.**, (hereinafter referred to as "ASSIGNEE"), a corporation of Spain, having a place of business at Barcelona Avda. Mare de Deu de Montserrat, 12; respectively, its successors, assigns and legal representatives, the entire right, title and interest for the United States, Canada, Japan and the member countries of the European Union as of May 1, 2017, in and to the invention which is disclosed in the International PCT Application No. **PCT/US2016/033965**, filed on **May 24, 2016**, which claims priority to the following: Chinese Patent Applications: 201510271449.6 filed May 25, 2015; 201510430387.9 filed July 21, 2015; 201510648574.4 filed October 10, 2015; and 201610099672.1 filed February 24, 2016, and which PCT Application is entitled

### **PROCESSES TO PRODUCE BRIVARACETAM**


and in and to said application and all provisional, divisional, continuing, substitute, renewal, reissue, and all other applications for Letters Patent which have been or shall be filed in the United States, Canada, Japan and the member countries of the European Union as of May 1, 2017 on said invention, and in and to all original, reissued and other patents and certificates of invention which


have been or shall be issued in the United States and Canada, Japan and the member countries of the European Union as of May 1, 2017 on said invention;

Agree that said Assignee may apply for and receive Letters Patent for said invention in its own name, and that, when requested, without further consideration from or charge to, but at the expense of said Assignee, its successors, assigns and legal representatives, to carry out in good faith the intent and purpose of this assignment, the undersigned will execute all divisional, continuing, substitute, renewal, reissue, and all other patent applications on said invention; execute all rightful oaths, assignments, powers of attorney and other papers; communicate to said Assignee, its successors, assigns, and representatives, all facts known to the undersigned relating to said invention and the history thereof; and generally do everything possible which said Assignee, its successors, assigns or representatives shall consider desirable for aiding in securing and maintaining proper patent protection for said invention and for vesting title to said invention and all applications for patents and all patents on said invention, in said Assignee, its successors, assigns and legal representatives; and

Covenant with said Assignee, its successors, assigns and legal representatives that no assignment, grant, mortgage, license or other agreement affecting the rights and property herein conveyed has been made to others by the undersigned, and that full right to convey the same as herein expressed is possessed by the undersigned.

Date: 06/12/2017  
month/day/year

  
Suzhou PengXu Pharmatech Co. Ltd. by Peng Wang

  
Witness

Xiangyong Gu  
Witness